Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era-Reference-Cited by-同舟云学术

Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era

Published:2018-12-04 Issue:5 Volume:184 Page:753-759
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Rivas-Delgado Alfredo¹^ORCID,Magnano Laura²³^ORCID,Moreno-Velázquez Miriam⁴,García Olga⁴,Nadeu Ferran⁵³,Mozas Pablo¹,Dlouhy Ivan¹,Baumann Tycho¹³,Rovira Jordina¹,González-Farre Blanca⁶³,Martínez Antonio⁶³,Balague Olga⁶³,Delgado Julio¹³^ORCID,Villamor Neus²³,Giné Eva¹³,Campo Elías²⁵³,Sancho-Cia Juan M.⁴,López-Guillermo Armando¹³

Affiliation:

1. Department of Haematology, Hospital Clínic; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Barcelona Spain

2. Haematopathology Unit, Department of Pathology, Hospital Clínic; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Barcelona Spain

3. CIBERONC; Barcelona Spain

4. Haematology Department, ICO-IJC-Hospital Germans Trias i Pujol; Universitat Autonoma de Barcelona; Badalona Spain

5. Lymphoid Neoplasm Program; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Barcelona Spain

6. Department of Pathology, Hospital Clínic; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Spain

Funder

Instituto de Salud Carlos III

Ministerio de Economía y Competitividad

Hospital Clínic de Barcelona

Institució Catalana de Recerca i Estudis Avançats

Publisher

Wiley

Subject